TUSTIN, Calif., Sept. 11 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL - News), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that at the stockholders' meeting held September 8th, the stockholders approved all of the matters set forth in the Proxy Statement dated July 14, 2006, including the acquisition of Jade Pharmaceuticals Inc. (JPI) and its two wholly owned People's Republic of China-based subsidiaries. The stockholders also approved a number of other proposals increasing the authorized capital stock and approving a reverse split of the outstanding shares.
